Literature DB >> 2340091

Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

M Blum1, D M Grant, W McBride, M Heim, U A Meyer.   

Abstract

N-Acetylation by hepatic arylamine N-acetyltransferase (NAT, EC 2.3.1.5) is a major route in the metabolism and detoxification of numerous drugs and foreign chemicals. NAT is the target of a common genetic polymorphism of clinical relevance in human populations. We have used our recently isolated rabbit cDNA rnat to clone three human NAT genes from human leukocyte DNA. None of the three genomic coding sequences was interrupted by introns. Two genes, designated NAT1 and NAT2, each possessed open reading frames of 870 bp. Both genes have been assigned to human chromosome 8, pter-q11. Following transfection they were transiently expressed in monkey kidney COS-1 cells. NAT1 and NAT2 gave rise to functional NAT proteins, as judged by their NAT enzyme activity with the arylamine substrate sulfamethazine. Western blots with NAT-specific antisera detected proteins of apparent molecular weight of 33 and 31 kD in NAT1- and NAT2-transfected cultures, respectively. The product of NAT2 had an identical apparent molecular weight as that of NAT detected in human liver cytosol. The deduced amino acid sequence of NAT2 also contained 6 peptide sequences which had previously been determined from tryptic peptides of the polymorphic NAT purified from human liver. These data suggest that NAT2 encodes the polymorphic NAT protein. The third gene, NATP, had multiple deleterious mutations and did not encode a functional NAT protein; it most likely represents a pseudogene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340091     DOI: 10.1089/dna.1990.9.193

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  101 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

2.  Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop.

Authors:  F Rodrigues-Lima; C Deloménie; G H Goodfellow; D M Grant; J M Dupret
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

3.  Prediction of drug response and safety in clinical practice.

Authors:  Andrew A Monte; Kennon J Heard; Vasilis Vasiliou
Journal:  J Med Toxicol       Date:  2012-03

4.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 5.  Polymerase chain reaction and its potential as a pharmacokinetic tool.

Authors:  M H Heim
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

6.  Molecular genotyping of N-acetylation polymorphism to predict phenotype.

Authors:  M Mashimo; T Suzuki; M Abe; T Deguchi
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

7.  A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

Authors:  C A Smith; M Wadelius; A C Gough; D J Harrison; C R Wolf; A Rane
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

Review 8.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-04-28       Impact factor: 4.132

9.  Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro.

Authors:  S L Kelly; E Sim
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

10.  Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.

Authors:  A E Cribb; B Tsui; R Isbrucker; R T Michael; C T Gillespie; J Brown-Bonomo; P Barrett; T Levatte; K W Renton
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.